{"schema_version":"secwatch.filing_event.v1","accession":"0001104659-25-074163","form_type":"8-K","ticker":"RIGL","cik":"0001034842","company_name":"RIGEL PHARMACEUTICALS INC","filed_at":"2025-08-05T23:59:59+00:00","discovered_at":"2026-05-14T18:02:43.165277+00:00","generated_at":"2026-05-17T20:22:10.185571+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Rigel Q2 net income $59.6M, revenue $101.7M; raises FY2025 guidance to $270-280M","bullets":["Q2 2025 total revenue $101.7M (net product sales $58.9M, up 76% YoY); net income $59.6M vs loss $1.0M in Q2 2024.","Raised FY2025 guidance: total revenue $270-280M (prev $200-210M); net product sales $210-220M (prev $185-192M).","Cash and investments increased to $108.4M from $77.3M at Dec 31, 2024.","TAVALISSE sales $40.1M (+52% YoY), GAVRETO $11.8M, REZLIDHIA $7.0M (+36%).","Completed enrollment in dose escalation part of Phase 1b study for R289 in R/R lower-risk MDS; dose expansion later this year."],"urls":{"canonical":"https://secwatch.observer/filing/0001104659-25-074163","json":"https://secwatch.observer/filing/0001104659-25-074163.json","markdown":"https://secwatch.observer/filing/0001104659-25-074163.md","text":"https://secwatch.observer/filing/0001104659-25-074163.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1034842/000110465925074163/0001104659-25-074163-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1034842/000110465925074163/tm2522417d2_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T20:22:10.185571+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}